Dec 15 2010
Reportlinker.com announces that a new market research report is available in its catalogue: Nanobiotechnology: Applications and Global Markets.
The total market for nanobiotechnology products is $19.3 billion in 2010 and is growing at a compound annual growth rate (CAGR) of 9% to reach a forecast market size of $29.7 billion by 2015.
Medical applications, including drug delivery and microbicides, dominate today's market, with sales of $19.1 billion in 2010. This market segment is growing at a compound annual growth rate (CAGR) of 8.7%, and is forecast to reach sales of $29 billion by 2015.
In the R&D tools market, DNA sequencing is an emerging growth opportunity for nanotechnologies. This sector is valued at $63 million in 2010 and is expected to increase at a 37% compound annual growth rate (CAGR) to reach $305 million in 2015.
STUDY GOALS AND OBJECTIVES
BCC's goal for this study is to examine the status of current and emerging nanobiotechnologies and products and assess their worldwide growth potential over a 5-year period from 2010 to 2015. We are particularly interested in characterizing the nanobiotechnology market for drug delivery, diagnostics, R&D tools, microbicides, and DNA sequencing applications. A main focus of this report is drug delivery, where the majority of nanotechnology sales occur.
Our main objective is to present a comprehensive analysis of what constitutes the state-of-the-art for nanotech-enabled life science products and what the current and future commercial potential is for each of the key market segments.
REASONS FOR DOING THE STUDY
Nanotechnology is coming of age as a materials platform in multiple industries including the biotechnology industry. The unique properties that nanomaterials provide enable value-added performance in a range of life science applications, from encapsulating and releasing drugs to biologic imaging. At the same time, the drug industry is searching for ways to extend drugs coming off patent as well as to improve drug pharmacokinetics. The diagnostics industry is seeking ways to better image molecular events to meet demand for new medicines. Nanobiotechnology, representing a diverse range of applications and materials, is the result of these converging forces.
Several nanotechnology platforms are already established and providing significant revenues in drug delivery applications, as well as diagnostics, microbicides, and R&D tools. Significant nanotechnology drug formats include polymer, liposomal, and nanocrystal drugs. Diagnostic and microbicide formats include nanoparticles, quantum dots, and dendrimers. Nanopore formats are emerging in third-generation DNA sequencing applications.
Given the emerging nature of this industry, it is timely to analyze the key trends, markets, and industry dynamics to provide a useful basis for decision-making.
INTENDED AUDIENCE
We have compiled a study of the main nanomaterials that will be important in the five major end-user segments. We present the nanobiotechnologies and growth-driving forces, product types, key market applications, companies and alliances, future market potential, and product sales forecasts for the period 2009 through 2015. We project the future use of nano-enabled products for the key end-use segments: R&D tools, drug delivery, diagnostics, microbicides, and DNA sequencing.
We also examine the changing industry dynamics, key nanomaterials and their applications, and markets.
This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanomaterials, life sciences tools, biodefense, medical devices, polymers, DNA sequencing, and medical and biologic imaging materials.
It will also be of interest to manufacturers of quantum dots, dendrimers, nanoparticles, nanocrystals, nanopores, biochips, and polymer nanoparticles.
SCOPE OF REPORT
The study scope includes the major nanotechnology formats that are likely to become commercialized within the next 5 years. Each technology format is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2010 through 2015. Technology issues and market-driving forces are discussed.
Influencing factors, including drug delivery needs, biologic imaging trends, industry structure, and patent trends, are also discussed.
BCC examines nanobiotechnology companies and industry alliances, nanomaterial consumption by end-user industry, and market-driving forces. We profile 115 nanobiotechnology companies.
METHODOLOGY
BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, drug delivery, diagnostics, next-generation DNA sequencing, and microbicides.
Based on our analysis, we evaluate the potential applications of nanomaterial platforms in each of the major market segments and forecast sales revenues for 2010 through 2015.
For research tools and drug discovery and development, the study presents a forecast from 2010 through 2015 for each of the important nanomaterials and applications. For drug delivery, we forecast the market by nanomaterial and by clinical indication. For diagnostics, the report forecasts from 2010 through 2015 the demand by application, modality, and nanomaterial. For microbicides, the report forecasts from 2010 through 2015 the demand by application and nanomaterial. For DNA sequencing, the study forecasts market size by use and by sequencing generation. Finally, we forecast the overall nanobiotechnology market by geographical region.
INFORMATION SOURCES
BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tool firms, diagnostics firms, drug firms, nanomaterials firms, and leading nanotechnology research institutions. In addition, we compiled data from secondary sources including industry, trade, and government
ANALYST CREDENTIALS
John Bergin has written previous BCC Research biotechnology reports, titled Epigenomics: DNA Sequencing: Emerging Technologies and Applications; Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-Chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; Synthetic Biology: Emerging Global Markets; Biologic Imaging Reagents: Technologies and Global Markets. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with a nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.
Source: http://www.reportlinker.com/